SCHEMBL2408055

SCHEMBL2408055

Cc1ccc(OB(c2ccc(C)c(Cl)c2)c2ccccc2N)cc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 3/20 0.38
▸ DRD2 P14416 1/20 0.36
▸ DRD4 P21917 1/20 0.36
▸ DRD3 P35462 1/20 0.36
▸ LMNA P02545 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ CD44 P16070 1/20 0.33
▸ PLA2G7 Q13093 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.31
▸ HTR2A P28223 1/20 0.31
▸ SLC6A4 P31645 1/20 0.31
▸ KCNH2 Q12809 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ POLB P06746 1/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ NPC1 O15118 1/20 0.30
▸ RAB9A P51151 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ ATM Q13315 1/20 0.30
▸ AR P10275 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12270700 0.78 CYP3A4 (0.41) CYP3A4CD44PLA2G7ALDH1A1TSHR
SCHEMBL2407880 0.71 CYP3A4 (0.46) CYP3A4DRD2DRD4DRD3CD44
SCHEMBL2406421 0.70 DRD2 (0.34) DRD2DRD4DRD3LMNASMN1; SMN2
SCHEMBL12270732 0.70 ALDH1A1 (0.46) CYP3A4LMNASMN1; SMN2ALDH1A1TSHR
SCHEMBL29116273 0.69 DRD2 (0.43) CYP3A4DRD2DRD4DRD3LMNA
SCHEMBL14503472 0.69 IDO1 (0.38) CYP3A4DRD3LMNAALDH1A1HTR2A
SCHEMBL2405725 0.69 DRD2 (0.39) DRD2DRD4DRD3LMNASMN1; SMN2
SCHEMBL4968436 0.68 CYP3A4 (0.43) CYP3A4LMNASMN1; SMN2CD44ALDH1A1
SCHEMBL2406396 0.68 DRD2 (0.38) DRD2DRD4DRD3LMNASMN1; SMN2
SCHEMBL2408644 0.67 SCN4A (0.42) DRD2DRD4DRD3LMNASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853424-B2 Protein cross-linking inhibitor JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2014-10-07 — — US disclosed
US-20110212919-A1 PROTEIN CROSS-LINKING INHIBITOR JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2011-09-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212919-A1 PROTEIN CROSS-LINKING INHIBITOR BAZ2B, PRMT1, BRIX1 CYP3A4 3743/4885DRD2 3904/4885DRD4 4304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback